Data from the COMMIT trial demonstrated that the addition of oxaliplatin, leucovorin, 5-fluorouracil (mFOLFOX6) and ...

About 15,000 registered nurses at several of New York City’s major hospitals walked off the job Jan 12 after contract ...

When a patient with renal cell carcinoma (RCC) progresses on or following the combination of a tyrosine kinase inhibitor (TKI ...

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 ...

Data from the longitudinal ColoCare study (NCT02328677) of patients with colorectal cancer add to a growing body of evidence ...

We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of ...

When we examine vicarious trauma in Latino and other communities of color, we cannot separate individual experience from the ...

The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...

Welcome to Onc Nurse On Call, the new podcast from Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Riley Kandel | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.